Events calendar
Please join us for a special seminar on Thursday 15th September, from 15.00-16.00, to hear from from Dr Patrick Kierkegaard (CRUK Convergence Science Centre), Dr Melody Zhifang Ni (NIHR London-IVD), and Dr Emma Harris (The Institute of Cancer Research).
The Converging on Cancer seminar series is back! In this series of webinars brought to you by the Cancer Research UK Convergence Science Centre at Imperial College London and The Institute of Cancer Research, London, researchers across the two organisations will discuss key challenges facing cancer research and opportunities for new convergence science approaches to address these. Hosted by the Convergence Science Centre's Scientific Director Professor Axel Behrens, the series aims to support the Centre's mission to facilitate collaboration between traditionally separate and distinct disciplines to address challenges in cancer and bring pioneering treatments to cancer patients faster.
This time we are hosting a special seminar on Thursday 15th September, from 15.00-16.00, exploring how we can support the translation of your research with the help of Dissemination and Implementation science. Please join us to hear from Dr Patrick Kierkegaard (CRUK Convergence Science Centre), Dr Melody Zhifang Ni (NIHR London-IVD), and Dr Emma Harris (The Institute of Cancer Research). The CRUK Convergence Science Centre offers expertise specifically into identifying facilitators into clinical adoption and streamlining innovative technologies into the NHS with respect to cancer technologies & methodologies, medical devices and biomarkers that are developed across The Institute of Cancer Research and Imperial College London. Our human factors & implementation science researcher Dr Kierkegaard can use a combination of qualitative and quantitative methods to generate evidence designed to support the development and adoption of technologies, in particular for non-invasive point of care devices. Using systems analysis, usability evaluation, stakeholder interviews and process mapping research, advice can be provided at the initial project design stage, for follow-up funding applications or during clinical implementation to ensure the greatest scope for clinical utility. To learn more about our Dissemination & Implementation science initiative, visit our website.
Dr Melody Zhifang Ni – NIHR London-IVD, Department of Surgery and Cancer, Imperial College London
“One-stop shop evidence generation at NIHR London IVD to support medtech translation”
Evidence is key to translate innovative ideas throughout the product lifecycle. Since 2013, NIHR London IVD has been working with patient representatives, developers, innovators, regulators and healthcare providers etc to gain an understanding of what such evidence looks like, and how such evidence could enable truly beneficial technologies to be developed and implemented in healthcare. This short presentation will briefly outline the range of tools LIVD has developed including POCKET (point of care key evidence checklist), LAMP (lean and agile multi-attribute process) and the Biomarker toolkit.
Melody Ni is Senior Research Fellow at the Department of Surgery and Cancer. She leads on decision analysis research stream within NIHR London IVD. Her work focuses on improving the quality of decision making, through tools, processes, education and training. She is passionate about technologies – identifying and enabling those that are truly beneficial and has the potential to change people’s lives for the better, grounded in an understanding of their enormous potential and their multi-faceted impact on people’s lives.
Dr Patrick Kierkegaard – CRUK Convergence Science Centre
“Define, De-risk, and Develop: How the Convergence Centre can help you create a value for your innovation and de-risk translational challenges from an early-stage”
Having a good idea and developing a cutting-edge innovation is not enough to get it translated into the real-world. You need to present it to the world and convince people, funders, regulators, and the NHS that your innovation will bring value to them. The CRUK Convergence Centre has the research infrastructure to support clinicians and scientists in this process. In this talk, I will present an overview of how the Convergence Centre applies Human Factors and Implementation Science methodologies to support clinicians & scientists create value for their innovation.
Patrick is a Human factors & Implementation Science researcher at the CRUK Convergence Science Centre and NIHR London In Vitro Diagnostics Co-operative at Imperial College London. He is an expert in producing evidence to assess the feasibility and barriers of introducting new ground-breaking technologies, software, and diagnostics before they are used in real life scenarios.
Dr Emma Harris – Division of Radiotherapy & Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
“Clinical implementation of elastography to monitor the treatment response of cancer to radiation therapy”
My group has developed a novel ultrasound technique, vibrational shear wave elastography (VSWE, to probe the biomechanical properties of tumours which may be used to assess tumour response. The next step is to design a clinical system for test in human subjects. This talk will discuss how Patrick Kierkegaard is helping us to gain crucial understanding of the exact clinical needs, any practical or perceptual barriers to implementation, and the potential impact and costs of VSWE, information essential to inform the system design and optimise the success of initial clinical studies.
Dr Emma Harris is Reader of Imaging and Radiation Physics at the Institute of Cancer Research in London, UK. Her research focuses on the application of radiation physics, ultrasound physics and image processing to improve cancer therapy. Recent work includes the development of novel ultrasound imaging technology that can probe the tumour microenvironment, both in the preclinical and clinical setting.
Please note: This webinar is exclusively available to colleagues from the Institute of Cancer Research, the Royal Marsden, Imperial and Imperial College Healthcare.